HomeScienceGeneticsUnited States Molecular Diagnostics Market Report 2022-2027 With Prominent Players

United States Molecular Diagnostics Market Report 2022-2027 With Prominent Players

Company logo

Dublin, Nov. 21, 2022 (GLOBE NEWSWIRE) — The “U.S. Molecular Diagnostics Market, Size, Share, Forecast 2022-2027, Industry Trends, Growth, Insights, Impact of COVID-19, Business Analysis” report added ResearchAndMarkets.coms offer.

The molecular diagnostics market in the United States is expected to reach $12.5 billion by 2027

Detecting genetic abnormalities is called molecular diagnostics. It aims to make detection, diagnosis, subclassification, prognosis and monitoring of therapeutic response easier.

In addition, it is a set of tools for analyzing biological markers in the genome and proteome and how cells transfer their genes as proteins. It is used in medical diagnostics. Molecular diagnostics has emerged over the past decade as a superior methodology in the United States, achieving the goal of faster disease diagnosis with less complexity. The market for these procedures is increasing, particularly for infectious disease diagnoses.

COVID-19 benefited the molecular diagnostics industry

Technological improvements, an aging population and rising demand for genetic testing are contributing to the growth of the market.

Furthermore, the increasing demand for POC testing can be attributed to the increasing need for self-testing and increased patient knowledge about faster diagnostics. In contrast, increased use of molecular diagnostics is likely to provide profitable growth prospects. However, over the projection period, the market is expected to be constrained by strict regulatory requirements to approve new molecular diagnostic techniques.

COVID-19 Impact on the US Molecular Diagnostics Market

The COVID-19 epidemic has led to widespread disruption to hospital workflows. The COVID-19 outbreak is expected to drive the growth of the molecular diagnostics market in the United States.

Must Read
AAOpt 2022: Genetic testing at AMD

The COVID-19 pandemic put a strain on global healthcare systems, necessitating the establishment of diagnostic devices and diagnostic service centers. The demand for real-time polymerase chain reaction testing (RT-PCR) to detect COVID-19 has increased as the number of COVID-19 patients has increased. Due to these factors, the market has greatly expanded in the year 2022 and 2023.

By-products, the reactants Segment accounts for dominance

According to our estimates, the reagent category will hold the largest market share in 2021. Due to its widespread use in research and clinical contexts, it is expected to maintain its supremacy in the years to come. Standard reagents help produce timely and accurate findings.

Due to standardized results, increased efficiency and cost-effectiveness, the market is expected to rise. During the pandemic, the increasing use of devices to detect the coronavirus, which had previously been developed for other infectious diseases, further boosted the market growth.

For example, Roche Diagnostics expanded its portfolio of Covid RT-PCR assays with the new Cobas 5800 system in February 2022 in countries that accepted the CE mark.

The oncology segment is growing at a high growth rate

By application, in this analysis, we analyzed the markets for infectious diseases, blood screening, genetic testing, and oncology testing. In the molecular diagnostics market in the United States, the infectious disease category held the largest market share in 2021. The dominance of this sector is due to the increased use of molecular diagnostics, especially PCR testing, for the diagnosis of COVID-19.

On the other hand, the oncology department is predicted to increase rapidly over the projection period. Cancer is the second leading cause of death in the United States.

Must Read
Genetic markers for autism, hidden in plain sight

In addition, in January 2021, the British In Vitro Diagnostics Association sought to request NHS England to establish a directive framework for molecular diagnostics in oncology. This is aimed at increasing acceptance and access to molecular diagnostics in oncology.

Due to technology, the in-situ hybridization segment is expected to witness market growth

The sequence specificity of in situ hybridization is a critical application that aids in understanding pathogenic processes and performing molecular tests for cancer diagnosis, monitoring and treatment.

Identifying and studying mRNA expression in preserved tissue samples using probes that complement the sequence of interest and molecular diagnostics of chromosomal integrity using Fluorescence ISH are two fundamental applications of ISH technology (FISH). This technology segment is predicted to develop over the forecast period due to the use of ISH technology for cancer diagnosis, an older population more susceptible to cancer and the introduction of new products.

End-use insights are prevalent in the US molecular diagnostics market

Due to large procedural volumes for Covid testing in central laboratories, laboratories are expected to gain market share as end-users in 2021.

Another key driver that is expected to boost the market is increased government initiatives to provide various services such as payment for diagnostic tests. The evolution of molecular diagnostic platforms used in PoC scenarios is gaining popularity. In March 2020, Abbott announced the ID NOW COVID-19 test, a molecular point-of-care test that diagnoses COVID-19 in less than 5 minutes.

Key business insights

Roche Diagnostics, Abbott Laboratories, Myriad Genetics, BioMerieux SA, Qiagen NV, Hologic (Gen-Probe), Danaher Corporation, Bio-rad laboratories, Inc. and GenMark Diagnostics are some of the prominent participants in the global molecular diagnostics industry.

Must Read
Interview with Thijs Hendrix: 'Fund consolidation and growth'

Mergers and acquisitions are used by the big companies to improve product capabilities and advertise their services. Optimal research and development techniques, robust supply chain network, increased investment in research and development and cost containment are expected to help the aforementioned vital players lead this market over the projection period.

Businesses covered

Main topics:

1 Introduction

2. Research Methodology

3. Summary

4. Market Dynamics
4.1 Growth engines
4.2 Challenges

5. US molecular diagnostics market

6. Market Share – Molecular Diagnostics Analysis in United States
6.1 On Products
6.2 By Application
6.3 By technology
6.4 By End User

7. Product – US molecular diagnostics market
7.1 Reagents
7.2 Instruments
7.3 Others

8. Application – US molecular diagnostics market
8.1 Infectious Disease
8.2 Blood Test
8.3 Genetic Testing
8.4 Oncological Testing

9. Technology – Molecular Diagnostics Market in United States
9.1 Polymerase Chain Reaction
9.2 In Situ Hybridization
9.3 Isothermal reinforcement
9.4 Sequence
9.5 Mass Spectrometry
9.6 Chips and Microarrays

10. End User – US Molecular Diagnostics Market
10.1 Laboratories
10.2 Hospital & Clinics
10.3 Other End User

11. Business Analysis
11.1 Overview
11.2 Recent Development
11.3 Revenues

For more information on this report visit https://www.researchandmarkets.com/r/g1zkjq

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments